# Achieve Life Sciences, Inc.: financial statements, quarterly

ACHV · Nasdaq · CIK 949858 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/achv.md) · [Financials](/companies/achv/financials.md) · [Filings](/companies/achv/filings.md) · [Insiders](/companies/achv/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/achv/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [3.6](/filings/0000950170-24-123375.md) | [2.1 d](/filings/0000950170-25-036831.md) | [2.8](/filings/0000950170-25-069806.md) | [5.1](/filings/0000950170-25-104571.md) | [7.6](/filings/0001193125-25-268074.md) | [7.3 d](/filings/0000950170-25-036831.md) | [7.1](/filings/0000950170-25-069806.md) | [6.7](/filings/0000950170-25-104571.md) | [5.3](/filings/0001193125-25-268074.md) | not reported | not reported | not reported |
| Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | [0.8](/filings/0000950170-24-123375.md) | [0.8 d](/filings/0000950170-24-038049.md) | [0.8](/filings/0000950170-24-056929.md) | [0.8](/filings/0000950170-24-096193.md) | [0.4](/filings/0000950170-24-123375.md) | [0.2 d](/filings/0001193125-26-120690.md) | [0.2](/filings/0001193125-26-218177.md) | [0.2](/filings/0001193125-26-344624.md) | [0.2](/filings/0001193125-25-268074.md) | [0.3 d](/filings/0001193125-26-120690.md) | [0.3](/filings/0001193125-26-218177.md) | [0.3](/filings/0001193125-26-344624.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(7.1)](/filings/0000950170-24-123375.md) | [(5.5) d](/filings/0001193125-26-120690.md) | [(6.5)](/filings/0001193125-25-268074.md) | [(8.5)](/filings/0001193125-25-268074.md) | [(12.5)](/filings/0001193125-25-268074.md) | [(12.4) d](/filings/0001193125-26-120690.md) | [(12.8)](/filings/0001193125-26-344624.md) | [(12.7)](/filings/0001193125-26-344624.md) | [(14.4)](/filings/0001193125-25-268074.md) | [(14.7) d](/filings/0001193125-26-120690.md) | [(10.2)](/filings/0001193125-26-344624.md) | [(74.8)](/filings/0001193125-26-344624.md) |
| Diluted EPS | $ per share | [(0.34)](/filings/0000950170-24-123375.md) | not reported | [(0.26)](/filings/0000950170-25-069806.md) | [(0.25)](/filings/0000950170-25-104571.md) | [(0.36)](/filings/0001193125-25-268074.md) | not reported | [(0.37)](/filings/0001193125-26-218177.md) | [(0.37)](/filings/0001193125-26-344624.md) | [(0.28)](/filings/0001193125-25-268074.md) | not reported | [(0.19)](/filings/0001193125-26-218177.md) | [(0.80)](/filings/0001193125-26-344624.md) |
| Basic EPS | $ per share | [(0.34)](/filings/0000950170-24-123375.md) | not reported | [(0.26)](/filings/0000950170-25-069806.md) | [(0.25)](/filings/0000950170-25-104571.md) | [(0.36)](/filings/0001193125-25-268074.md) | not reported | [(0.37)](/filings/0001193125-26-218177.md) | [(0.37)](/filings/0001193125-26-344624.md) | [(0.28)](/filings/0001193125-25-268074.md) | not reported | [(0.19)](/filings/0001193125-26-218177.md) | [(0.80)](/filings/0001193125-26-344624.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: not reported
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [19.9](/filings/0000950170-23-062028.md) | [15.5](/filings/0000950170-25-036831.md) | [66.4](/filings/0000950170-24-056929.md) | [14.8](/filings/0000950170-24-096193.md) | [9.5](/filings/0000950170-24-123375.md) | [12.8](/filings/0001193125-26-120690.md) | [13.0](/filings/0000950170-25-069806.md) | [51.9](/filings/0000950170-25-104571.md) | [31.9](/filings/0001193125-25-268074.md) | [20.9](/filings/0001193125-26-344624.md) | [28.1](/filings/0001193125-26-218177.md) | [48.0](/filings/0001193125-26-344624.md) |
| Current assets | $m | [21.9](/filings/0000950170-23-062028.md) | [17.0](/filings/0000950170-25-036831.md) | [67.7](/filings/0000950170-24-056929.md) | [62.5](/filings/0000950170-24-096193.md) | [45.5](/filings/0000950170-24-123375.md) | [36.5](/filings/0001193125-26-120690.md) | [25.0](/filings/0000950170-25-069806.md) | [56.9](/filings/0000950170-25-104571.md) | [50.1](/filings/0001193125-25-268074.md) | [39.9](/filings/0001193125-26-344624.md) | [31.1](/filings/0001193125-26-218177.md) | [188](/filings/0001193125-26-344624.md) |
| Total assets | $m | [24.3](/filings/0000950170-23-062028.md) | [19.4](/filings/0000950170-25-036831.md) | [70.0](/filings/0000950170-24-056929.md) | [64.8](/filings/0000950170-24-096193.md) | [47.9](/filings/0000950170-24-123375.md) | [38.6](/filings/0001193125-26-120690.md) | [27.4](/filings/0000950170-25-069806.md) | [58.9](/filings/0000950170-25-104571.md) | [52.0](/filings/0001193125-25-268074.md) | [41.8](/filings/0001193125-26-344624.md) | [33.1](/filings/0001193125-26-218177.md) | [190](/filings/0001193125-26-344624.md) |
| Current liabilities | $m | [4.1](/filings/0000950170-23-062028.md) | [20.8](/filings/0000950170-25-036831.md) | [20.6](/filings/0000950170-24-056929.md) | [13.7](/filings/0000950170-24-096193.md) | [6.7](/filings/0000950170-24-123375.md) | [6.7](/filings/0001193125-26-120690.md) | [7.1](/filings/0000950170-25-069806.md) | [8.6](/filings/0000950170-25-104571.md) | [9.7](/filings/0001193125-25-268074.md) | [9.1](/filings/0001193125-26-344624.md) | [11.8](/filings/0001193125-26-218177.md) | [198](/filings/0001193125-26-344624.md) |
| Total liabilities | $m | [20.3](/filings/0000950170-23-062028.md) | [20.8](/filings/0000950170-25-036831.md) | [20.6](/filings/0000950170-24-056929.md) | [22.5](/filings/0000950170-24-096193.md) | [16.5](/filings/0000950170-24-123375.md) | [17.7](/filings/0001193125-26-120690.md) | [17.1](/filings/0000950170-25-069806.md) | [17.3](/filings/0000950170-25-104571.md) | [18.4](/filings/0001193125-25-268074.md) | [20.3](/filings/0001193125-26-344624.md) | [22.4](/filings/0001193125-26-218177.md) | [205](/filings/0001193125-26-344624.md) |
| Shareholders' equity | $m | [4.0](/filings/0000950170-24-123375.md) | [(1.4)](/filings/0001193125-26-120690.md) | [49.5](/filings/0001193125-25-268074.md) | [42.3](/filings/0001193125-25-268074.md) | [31.4](/filings/0001193125-25-268074.md) | [20.9](/filings/0001193125-26-344624.md) | [10.3](/filings/0001193125-26-344624.md) | [41.7](/filings/0001193125-26-344624.md) | [33.6](/filings/0001193125-25-268074.md) | [21.5](/filings/0001193125-26-344624.md) | [10.7](/filings/0001193125-26-344624.md) | [(14.7)](/filings/0001193125-26-344624.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(5.1) d](/filings/0000950170-24-123375.md) | [(4.4) d](/filings/0001193125-26-120690.md) | [(5.3)](/filings/0000950170-25-069806.md) | [(4.9) d](/filings/0000950170-25-104571.md) | [(10.4) d](/filings/0001193125-25-268074.md) | [(9.2) d](/filings/0001193125-26-120690.md) | [(11.1)](/filings/0001193125-26-218177.md) | [(9.1) d](/filings/0001193125-26-344624.md) | [(11.3) d](/filings/0001193125-25-268074.md) | [(18.0) d](/filings/0001193125-26-120690.md) | [(6.9)](/filings/0001193125-26-218177.md) | [(10.8) d](/filings/0001193125-26-344624.md) |
| Capital expenditure | $m | not reported | [0.0 d](/filings/0001193125-26-120690.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [9.7](/filings/0000950170-23-062028.md) | [17.9](/filings/0000950170-24-056929.md) | [19.0](/filings/0000950170-24-096193.md) | [21.1](/filings/0000950170-24-123375.md) | [25.0](/filings/0000950170-25-069806.md) | [34.3](/filings/0000950170-25-104571.md) | [34.4](/filings/0001193125-25-268074.md) | [34.7](/filings/0001193125-26-218177.md) | [34.7](/filings/0001193125-26-344624.md) | [51.0](/filings/0001193125-25-268074.md) | [53.4](/filings/0001193125-26-218177.md) | [93.5](/filings/0001193125-26-344624.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 102,902,490 at 2026-08-11, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344624.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.